Back to top
more

OptimizeRx (OPRX)

(Delayed Data from NSDQ)

$12.50 USD

12.50
231,761

-0.12 (-0.95%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $12.48 -0.02 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 246)

Industry: Computer - Software

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Best Growth Stocks to Buy for August 1st

by Zacks Equity Research

OPRX, JBL and ADRNY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 1, 2025.

Brian Bolan headshot

Bull Of The Day: OptimizeRX (OPRX)

by Brian Bolan

This stock is reporting earnings next week and posting positive operating margins is going to be key.

Indrajit Bandyopadhyay headshot

Does OptimizeRx Have a Moat in the Crowded HealthTech Space?

by Indrajit Bandyopadhyay

OPRX's subscription shift, DAAP platform, and HCP-DTC reach suggest a moat is forming-but is it built to last?

Zacks Equity Research

Blackbaud (BLKB) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Blackbaud (BLKB) delivered earnings and revenue surprises of +15.24% and +1.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus

by Santanu Roy

AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.

Indrajit Bandyopadhyay headshot

OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?

by Indrajit Bandyopadhyay

OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.

Zacks Equity Research

Best Growth Stocks to Buy for July 22nd

by Zacks Equity Research

OPRX, ADRNY and DELL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 22, 2025.

Indrajit Bandyopadhyay headshot

Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?

by Indrajit Bandyopadhyay

OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.

Indrajit Bandyopadhyay headshot

OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?

by Indrajit Bandyopadhyay

OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.

Zacks Equity Research

Synopsys (SNPS) Moves 3.6% Higher: Will This Strength Last?

by Zacks Equity Research

Synopsys (SNPS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Indrajit Bandyopadhyay headshot

OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?

by Indrajit Bandyopadhyay

OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.

Zacks Equity Research

Best Growth Stocks to Buy for July 9th

by Zacks Equity Research

OPRX, EWCZ and QFIN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 9, 2025.

Indrajit Bandyopadhyay headshot

Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?

by Indrajit Bandyopadhyay

OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.

Indrajit Bandyopadhyay headshot

OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?

by Indrajit Bandyopadhyay

OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.

Zacks Equity Research

Best Growth Stocks to Buy for June 25th

by Zacks Equity Research

OPRX, GLDD and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 25, 2025

Zacks Equity Research

Here's Why OptimizeRx Corp. (OPRX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

New Strong Buy Stocks for June 4th

by Zacks Equity Research

BCRX, OPRX, BWB, PLMR and RACE have been added to the Zacks Rank #1 (Strong Buy) List on June 4, 2025.

Zacks Equity Research

DSGX's Solution Used by ArrowXL to Boost Last Mile Delivery

by Zacks Equity Research

Descartes announces that ArrowXL is leveraging its cloud-based route planning and execution solution to streamline last mile delivery operations.

Zacks Equity Research

Earnings Estimates Rising for OptimizeRx (OPRX): Will It Gain?

by Zacks Equity Research

OptimizeRx (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

OptimizeRx Corp. (OPRX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

OptimizeRx (OPRX) delivered earnings and revenue surprises of 172.73% and 15.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Microsoft (MSFT) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Microsoft (MSFT) delivered earnings and revenue surprises of 8.13% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cadence Design Systems (CDNS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Cadence (CDNS) delivered earnings and revenue surprises of 5.37% and 0.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OptimizeRx (OPRX) delivered earnings and revenue surprises of 20% and 9.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Oracle (ORCL) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Oracle (ORCL) delivered earnings and revenue surprises of -0.68% and 1.59%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

OptimizeRx (OPRX) delivered earnings and revenue surprises of 100% and 14.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?